博雅生物(300294.SZ)：已向博雅(廣東)預付總計約8.23億元原料血漿採購款
格隆匯 9 月 14日丨博雅生物(300294.SZ)公佈，經公司第六屆董事會第二十三次會議、第六屆監事會第二十次會議，以及2019年第一次臨時股東大會審議，通過了《關於採購廣東丹霞生物製藥有限公司原料血漿暨關聯交易的議案》，公司向丹霞生物(現更名為：博雅生物製藥(廣東)有限公司，“博雅(廣東)”)採購不超過500噸的原料血漿，採購價格不超過165萬元/噸,金額不超過8.25億元，公司與博雅(廣東)簽訂了《原料血漿供應框架協議》。詳見公司2019年4月15日披露的《關於採購廣東丹霞生物製藥有限公司原料血漿暨關聯交易的公告》。截至目前，公司已向博雅(廣東)預付總計約8.23億元的原料血漿採購款。
為保障血漿供應，進一步提高公司持續盈利能力，公司一方面通過調撥的方式申請，一方面通過改變供漿關係的方式申請，積極推進博雅生物採購博雅(廣東)原料血漿事項，希望努力盡快實現血漿採購。
根據《血液製品管理條例》的規定，“單採血漿站只能向一個與其簽訂質量責任書的血液製品生產單位供應原料血漿，嚴禁向其他任何單位供應原料血漿。”鑑於目前的政策環境及現行的法規條件，截至本公告披露日，公司向博雅(廣東)採購原料血漿事項採取“調撥申請”方式未能獲得批准。
基於原料血漿的稀缺性，以及血液製品在新型冠狀病毒肺炎疫情中發揮積極重要作用，為充分利用血漿資源，根據《單採血漿站管理辦法》第四十三條“單採血漿站只能向設置其的血液製品生產單位供應原料血漿”、第十九條“設置單採血漿站的血液製品生產單位發生變更的，該單採血漿站應當重新辦理《單採血漿許可證》，原《單採血漿許可證》註銷”等規定。公司與博雅(廣東)正積極推進“改變供漿關係”的申請工作，變更“設置單採血漿站的血液製品生產單位”，將單採血漿站由博雅(廣東)的設置變更為博雅生物設置。“改變供漿關係”申請尚需獲得衞生健康委員會相關部門的審批，該事項能否獲得批准，以及獲批的時間均存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
